AISeeking Alphaabout 4 hours ago
AbCellera: AI Antibody Platform Near Cash Value
1 min read
AbCellera, the antibody platform behind two authorized COVID-19 therapies, holds over $650M in liquidity against a roughly $1.6B market cap. The stock trades near $5, down more than 90% from its 2021 high. The author initiated coverage with a Buy rating, calling it an asymmetric, catalyst-driven bet.
Level
Hype check
Tap to vote and see what everyone thinks.
